SMMT Stock: Price, Earnings History and SEC Filings
Summit Therapeutics Inc. (SMMT) last traded at $16.03, down 1.05% on the latest session and down 5.2% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.28 against an analyst estimate of $-0.26, a miss of 7.7%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
SMMT earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 23, 2026 | $-0.28 | $-0.26 | -7.69% |
| Mar 2026 | Apr 30, 2026 | $-0.24 | $-0.33 | +27.27% |
| Dec 2025 | Feb 23, 2026 | $-0.29 | $-0.22 | -31.82% |
| Sep 2025 | Oct 20, 2025 | $-0.31 | $-0.14 | -121.43% |
SMMT beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How SMMT reacts to earnings
Across its last 8 earnings releases, SMMT moved 11.1% on average the next session, in either direction. It rose after 2 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-07-23 | After close | -8.81% |
| 2026-04-30 | After close | -24.91% |
| 2026-02-23 | After close | +0.19% |
| 2026-01-12 | Before open | -13.41% |
| 2025-10-20 | Before open | -4.55% |
| 2025-08-11 | After close | -9.08% |
| 2025-05-01 | After close | +13.09% |
| 2025-02-24 | Before open | -14.83% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
SMMT financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2024 | $0 | -$221M | -$142M | – | $-0.31 |
| 2023 | $0 | -$615M | -$77M | – | $-0.99 |
| 2022 | $705000 | -$79M | -$42M | -11174.8% | $-0.41 |
| 2021 | $2M | -$89M | -$73M | -4897.8% | $-0.67 |
| 2020 | $860000 | -$53M | -$49M | -6127.6% | $-0.76 |
| 2019 | $57M | $11M | -$35M | 19.0% | $0.63 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for SMMT
- DEF 14A · Oct 19, 2026
- 8-K · Sep 29, 2026Material agreement, Unregistered share sale, Bylaw change
- 8-K · Sep 15, 2026Other events, Financial statements and exhibits
- 8-K · Sep 14, 2026Other events, Financial statements and exhibits
- 8-K · Sep 3, 2026Other events, Financial statements and exhibits
- 8-K · Aug 26, 2026Other events, Financial statements and exhibits
- 8-K · Aug 5, 2026Other events, Financial statements and exhibits
- 8-K · Jul 23, 2026Material agreement, Financial statements and exhibits
- 424B5 · Jul 23, 2026
- 10-Q · Jul 23, 2026
Insider filing activity
SMMT insiders filed 1 Form 4 report in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
SMMT news
- Summit Therapeutics (SMMT) Could Be 46% Undervalued On New Cancer Trials And AI DealOct 30, 2026 · finance.yahoo.com
- AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales GrowthOct 30, 2026 · finance.yahoo.com
- Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big CatalystsOct 26, 2026 · marketbeat.com
- Lunit and Summit to evaluate pathology platform for tumour analysisOct 26, 2026 · pharmaceutical-technology.com
- Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in ChinaOct 25, 2026 · finance.yahoo.com
- Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology DevelopmentOct 24, 2026 · finance.yahoo.com
- Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology DevelopmentOct 23, 2026 · finance.yahoo.com
- U.S. Treasury Wants to Rein In Deals for Chinese Biotech and AIOct 23, 2026 · finance.yahoo.com
About Summit Therapeutics Inc.
Summit Therapeutics Inc. (SMMT) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. Its fiscal year ends in December.